Brought to you by 
Roche to gain full ownership of Genentech in $43.7bn deal
15 Aug 2012
Executive Summary
Aiming to gain full ownership of the Top Biotech that has brought it much success in the cancer drug market, Roche intends to acquire the 44.1% of outstanding shares and options of Genentech (publicly traded) it doesn't already own for approximately $43.7bn. Roche says the deal would create the seventh-largest pharmaco by market share in the US, producing over $15bn in annual revenues.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Contract
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche to gain full ownership of Genentech in $43.7bn deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice